BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of ...

Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and ...

Becton, Dickinson and Company (NYSE:BDX) authorized to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions ...

American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic ...

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

BD announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD’s Biosciences and Diagnostic ...

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

BD (NYSE: BDX) announced that its board unanimously authorized management to pursue the separation of its Life Sciences business.

At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...

The plan is to position the New BD as a differentiated MedTech leader and enable optimized investment to accelerate the innovation pipeline and ongoing margin enhancement through BD Excellence to ...

In keeping with the trend in med tech to return to basics, Becton, Dickinson and Co. plans to split off its biosciences and diagnostic solutions unit to create two pure-play companies. The ‘New BD’ or ...

Becton Dickinson beat expectations for first-quarter results and said its board has authorized a plan to separate its biosciences and diagnostic solutions unit on Wednesday, as the medical device ...